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Retinoic acid suppresses IL-17 production and
pathogenic activity of γδ T cells in CNS autoimmunity
Mathilde Raverdeau1, Conor J Breen2, Alicja Misiak1 and Kingston HG Mills1
Retinoic acid (RA) in the steady state enhances induction of Foxp3+ regulatory T (Treg) cells and inhibits differentiation of Th1
and Th17 cells, thereby maintaining tolerance, but can in inflammatory conditions promote effector Th1 and Th17 cells that
mediate inflammation. IL-17-producing γδ T cells have recently been shown to have a major pathogenic role in autoimmune
diseases. Here, we examined the immunomodulatory effects of RA on γδ T cells. We found that RA had a dramatic suppressive
effect on IL-17A and IL-17F production by γδ T cells stimulated with IL-1β and IL-23. RA suppressed RORγt, IL-1R and
IL-23R expression in γδ T cells. Treatment of mice with RA suppressed IL-17 production by γδ T cells in vivo. Furthermore,
treatment of T cells with RA attenuated their ability to induce disease in experimental autoimmune encephalomyelitis (EAE),
a murine model for multiple sclerosis. This was associated with a reduction in the number of central nervous system-infiltrating
γδ T cells, but also CD4+ T cells that produced IL-17A, IL-17F or GM-CSF. Interestingly, treatment of γδ T cells with RA or
removal of γδ T cells from a bulk population of T cells significantly reduced their capacity to induce EAE, demonstrating a
critical role for γδ T cells in promoting pathogenic Th17 cells. Our findings demonstrate that the anti-inflammatory properties of
RA are mediated in part by suppressing STAT3-mediated activation of cytokine production and cytokine receptor expression in
γδ T cells, which suppresses their ability to activate Th17 cells.
Immunology and Cell Biology (2016) 94, 763–773; doi:10.1038/icb.2016.39
At the border between innate and adaptive immunity, γδ T cells
express T-cell receptor (TCR) that recognize non-major histo-
compatibility complex-restricted antigens, but also express receptors
for cytokines and Toll-like receptors. These cells are rapidly activated
upon inflammation, stress or infection, provide early sources of
cytokines such as IFN-γ, IL-17 and IL-21, and enhance immune
responses, for instance by influencing antigen-specific CD4+ T cells.1–3
In experimental autoimmune encephalomyelitis (EAE), a mouse
model for multiple sclerosis (MS), the role of γδ T cells, and
particularly of IL-17-producing γδ T cells has been the subject of
debate, although the consensus view is that they have a pathogenic role
in this disease.1,4–6 γδ T cells secrete IL-17 in response to stimulation
with IL-23 and IL-1β, IL-1α or IL-18, without TCR engagement.3,7
During development of EAE, IL-17+ γδ T cells and in particular the
Vγ4 subtype of γδ T cells are the first cells to produce IL-17 and are
found at high numbers in the brains of the mice early in the course of
disease.2,3,8 Moreover, mice lacking functional γδ T cells (TCRδ− /−
mice) have delayed and attenuated EAE and the production of IL-17A
by autoantigen-specific Th17 cells is reduced in these mice, indicating
that γδ T cells enhance the pathogenicity of CD4+ T cells in this
model.3,9 Activated γδ T cells also antagonize the anti-inflammatory
activity of regulatory T (Treg) cells and inhibit their differentiation,
thereby enhancing the activity of effector T cells that mediate the
development of EAE.2
Retinoic acid (RA), the active metabolite of vitamin A, is a powerful
immunomodulator, which, in the steady state, promotes immune
tolerance by enhancing Foxp3+ Treg cells and inhibiting the differ-
entiation of Th17 cells.10 However, in inflammatory conditions,
RA can promote effector Th1 and Th17 and thereby enhance
inflammation.11,12 AM80, a selective agonist of the RA nuclear
receptor-α (RARα) has been shown to have a protective effect in
the early stages of EAE by inhibiting the differentiation of pathogenic
Th17 cells.12–15 Administered at later stages of the disease, AM80
delays the recovery from EAE by inducing the apoptosis and
differentiation of immature myeloid-derived suppressor cells, a cell
population that exerts immunosuppressive effects on effector T cells.16
RA has also been shown to protect mice from EAE by inhibiting the
maturation of dendritic cells and monocytes thereby impairing their
antigen presentation function.17
We have previously reported that RA has a protective effect in a
mouse model of colitis by promoting IL-22 production by γδ T cells
and type 3 innate lymphoid cells (ILC3).18 Given the important role of
IL-17A-producing γδ T cells in the development of EAE, we addressed
the hypothesis that RA may be protective in EAE through modulating
the function of γδ T cells. We found that RA significantly inhibited
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IL-17A and IL-17F production by γδ T cells and CD4+ T cells
stimulated with IL-1β and IL-23, but the effect on γδ T cells was
more dramatic. Furthermore, treatment of γδ T cells with RA
significantly inhibited the capacity of T cells from myelin
oligodendrocyte glycoprotein (MOG)-immunized mice to induce
EAE by adoptive transfer. In addition, RA impaired the differentiation
of IL-17A-expressing γδ T cells by inhibiting RORγt expression and
downregulating expression of receptors for IL-1β and IL-23.
RESULTS
RA inhibits IL-17 production by γδ T cells in vitro and in vivo
We have previously demonstrated that γδ T cells secrete IL-17 and
IFN-γ following stimulation with IL-1β and IL-23 without TCR
activation, whereas CD4+ memory T cells secrete IL-17 following
stimulation with IL-1β and IL-23 in the presence of anti-CD3.3,19
Here, we examined the effect of RA on cytokine production by γδ
T cells. We found that RA suppressed IL-17 production by both γδ
T cells within a bulk population of spleen cells stimulated with IL-1β
and IL-23 (Figures 1a and b). IL-1β and IL-23 also induced IL-17
production by CD4+ T cells but only when co-stimulated with anti-
CD3 and this was also inhibited by co-culture with RA (Figures 1a
and b). We then examined the effect of RA on purified γδ T cells or
Vγ1+ or Vγ4+ γδ T cells from lymph nodes of naive mice. Stimulation
of γδ T cells with RA alone did not change basal cytokine production
(Figure 1c). Stimulation of γδ T cells with IL-1β and IL-23 induced
high concentrations of IL-17A and IL-17F, mainly by Vγ4+ T cells
(Figures 1c–e), as well as IFN-γ (Figure 1c). The addition of RA
significantly reduced the production of IL-17A and IL-17F (Figures 1c,
d and f). In contrast, RA did not affect the production of IFN-γ by γδ
T cells (Figure 1c and data not shown). The expression of the nuclear
receptor for RA, RARα, was 34 times higher in the IL-17-producing γδ
T cells (CD27−) when compared with γδ T cells that express IFN-γ
(CD27+) (Figure 1e). Interestingly, the expression of the transcription
factor RORγt, required for the production of IL-17, was impaired by
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Figure 1 RA impairs IL-17A but not IFN-γ production by γδ T cells and CD4+ T cells. (a, b) Spleen cells from naive mice were cultured for 3 days with
medium or anti-CD3 and in combination with IL-1β and IL-23 and in the presence or absence of RA. (a) Representative FACS plots of IL-17A expression by
γδ T cells and CD4+ T cells. (b) Mean absolute numbers of IL-17A+ and IFN-γ+ γδ T cells and CD4+ T cells in the cultures. (c–f) γδ T cells purified from
lymph nodes of naive mice were cultured for 3 days with IL-1β+IL-23, with or without RA. (c) IL-17A, IL-17F and IFN-γ concentration measured by ELISA in
the supernatants of purified γδ T cells cultured for 3 days with IL-1β+IL-23, with or without RA. (d) IL-17A and IL-17F concentration measured by ELISA in
the supernatants of purified Vγ1+ or Vγ4+ γδ T cells cultured for 3 days with IL-1β+IL-23, with or without RA. (e) Relative expression of rara in CD27+ and
CD27− γδ T cells purified by FACS. (f, g) Representative FACS plots (f) and mean frequencies (g) of Vγ1+ and Vγ4+ T cells expressing IL-17A and RORγt
after 3 days of culture with IL-1β+IL-23, with or without RA. Data are representative of three independent experiments. Bars are mean+s.d.; *Po0.05,
**Po0.01 and ***Po0.001, two-tailed unpaired t-test.
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RA in γδ T cells stimulated or not with IL-1β and IL-23, and
particularly in Vγ4+ T cells (Figures 1f and g).
We next assessed the effect of RA on cytokine production by γδ
T cells and CD4+ T cells in vivo. The production of IL-17A by γδ
T cells was strongly inhibited in mice injected with RA when
compared with mice injected with vehicle (Figures 2a and b). The
production of IL-17A by CD4+ T cells was also affected in the mice
injected with RA but to a lesser extent when compared with the effect
on γδ T cells (Figures 2a and b). In contrast, RA did not affect the
production of IFN-γ by γδ T cells or CD4+ T cells (Figure 2b).
RA inhibits IL-17 production by CD4 and γδ T cells from mice with
EAE
IL-17A-producing γδ T cells and CD4+ T cells (Th17 cells) have been
shown to have pathogenic roles in a range of autoimmune diseases,
including MS and EAE where they promote inflammation. It has
previously been reported that retinoids can attenuate development of
EAE.15,17 However, these studies did not examine the effect of RA on
γδ T cells. Having shown that RA impairs IL-17A production mainly
by γδ T cells but also by CD4+ T cells, we examined its effect on γδ
T cells and CD4+ T cells from mice with EAE. Mice were immunized
with the myelin antigen MOG emulsified in complete Freund’s
adjuvant and 10 days later their spleens and draining lymph nodes
cells were isolated and cultured with MOG, IL-1β and IL-23 to drive
the differentiation of IL-17-producing γδ T cells and Th17 cells, and in
the presence of RA or vehicle control. The production of IL-17A,
IL-17F and IFN-γ measured in the supernatant of the cultures by
ELISA was strongly attenuated by addition of RA (Figure 3a). We next
examined more closely the effect of RA on cytokine production by γδ
T cells and CD4+ T cells using intracellular cytokine staining and
fluorescence-activated cell sorting (FACS) analysis (Figures 3b and c)
or by RT-PCR performed on γδ T cells and CD4+ T cells sorted at the
end of the culture (Figure 3d). We found that RA inhibited IL-17A
principally in γδ T cells and particularly in the Vγ4+ γδ T cells, but
also in CD4+ T cells (Figures 3b–d). The expression of IL-17F was also
strongly reduced by RA in both γδ T cells and CD4+ T cells
(Figure 3d). Interestingly, the number of IFN-γ+ γδ T cells was
unchanged and the number of IFN-γ+ CD4+ T cells was increased by
RA (Figures 3b and c). However, assessment of other IFN-γ-producing
cell types by FACS indicated that RA impaired IFN-γ expression in
CD8+ T cells (data not shown). This may explain the overall reduction
in IFN-γ production detected by ELISA on cultures of mixed LN and
spleen cells stimulated with MOG, IL-1β and IL-23 (Figure 3a).
We also assessed the effect of RA on expression of the gene coding
for RORγt by RT-PCR in γδ T cells and CD4+ T cells purified from
the 3-day cultures and found that the expression of rorc was strongly
reduced by RA in both cell types (Figure 3e). We also found that the
proliferation of γδ T cells (but not CD4+ T cells) and more specifically
of the Vγ4+ γδ T cells was impaired by treatment with RA leading to a
reduced number of Vγ4+ γδ T cells in the culture (Figures 3f and g
and data not shown). Collectively, these findings demonstrated that
RA suppresses IL-17 production by γδ T cells and Th17 cells and
affects the polarization of these cells. Our data also show that RA has
the most pronounced inhibitory effect on activation and proliferation
of IL-17-secreting Vγ4+ γδ T cells.
RA suppresses the pathogenic function of γδ T cells and CD4+
T cells in the EAE model
Having shown that RA inhibits IL-17A and IL-17F production
principally by γδ T cell but also by CD4+ T cells from MOG-
immunized mice, we examined the effect of RA on the effector and
pathogenic function of these cells in EAE by adoptive transfer to naive
mice. Spleen and lymph nodes cells from mice immunized with MOG
and complete Freund’s adjuvant were cultured under Th17-polarizing
conditions (MOG, IL-1β and IL-23) in the presence of RA or a vehicle
control. After 3 days, the cells were washed thoroughly and transferred
to naive recipient mice (15× 106 cells per mouse). The mice injected
with the vehicle-treated cells developed signs of EAE by day 7
(Figure 4a). In contrast, the onset of EAE was delayed by several days
and the clinical signs of disease were strongly attenuated in mice
injected with the RA-treated cells (Figure 4a). An examination of
infiltrating lymphocytes in the brains of the mice 16 days after the cell
transfer revealed that the number of CD3+ T cells infiltrating the brains
was greatly reduced in the recipients of the RA-treated cells when
compared with the mice injected with the control cells (Figure 4b).
Moreover, the number of CD4+ T cells and γδ T cells and the
production of the cytokines IL-17A, IL-17F, IFN-γ and GM-CSF by
these cells were significantly lower in the brains of the animals injected
with the RA-treated cells when compared with the control group
(Figures 4c and d). Thus, RA decreased the production of IFN-γ,
IL-17A and IL-17F induced by IL-1β and IL-23 and particularly the
production of IL-17A and IL-17F by γδ T cells and Th17 (Figure 3),
which resulted in a reduced number of pathogenic γδ T cells and CD4+
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Figure 2 RA inhibits IL-17 production by γδ T cells and CD4+ T cells in vivo.
(a, b) Representative FACS plots (a) and absolute numbers (b) of IL-17A+ and
IFN-γ+ γδ T cells and CD4+ T cells isolated from peritoneal cavity 18 h after
injection of RA or vehicle only (dimethyl sulfoxide) and re-stimulation with
phorbol 12-myristate 13-acetate, ionomycin and brefeldin A. Bars are mean
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T cells infiltrating the brains and a consequent attenuation of the
clinical signs of EAE (Figure 4).
RA mediates immunomodulatory activity largely through its effect
on γδ T cells
As the impact of RA seemed particularly striking on γδ T cells
(Figures 1, 2 and 3), we examined more closely the effect of RA on the
pathogenic function of these cells. We first evaluated the importance
of γδ T cells in our EAE model by performing an adoptive transfer of
cells from MOG-immunized mice depleted of γδ T cells. Spleen and
lymph nodes cells from mice immunized with MOG and complete
Freund’s adjuvant were depleted of γδ T cells, or left un-separated,
before being stimulated for 3 days in Th17-polarizing conditions and
then transferred to recipient animals. Depletion of γδ T cells prior to
culture reduced the production of IL-17A, IL-17F and IFN-γ by the
spleen and lymph node cells (Figure 5a). Intracellular cytokine staining
and FACS showed that depletion of γδ T cells prior to culture
impaired the expansion of Tbet+ and RORγt+ CD4+ T cells (Th1 and
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Figure 3 RA suppresses IL-17 production and RORγt expression in CD4+ T cell and γδ T cell and impairs Vγ4+ T-cell proliferation under inflammatory
conditions. Mice were immunized subcutaneously with MOG emulsified in complete Freund’s adjuvant. Ten days after immunization, lymph node and spleen
cells were cultured together for 3 days with MOG, IL-1β and IL-23 and either RA or vehicle. (a) IL-17A, IL-17F and IFN-γ production was quantified in
supernatants by ELISA at the end of the 3-day culture. (b) Representative FACS plots of the IL-17A+ and IFN-γ+ CD4+ T cells and IL-17A+ Vγ4+ γδ T cells
at the end of the 3-day culture. (c) Mean absolute numbers of IL-17A+ and IFN-γ+ CD4+ T cells and γδ T cells at the end of the 3-day culture. (d, e)
Relative expression of il17a, il17f (d) and rorc (e) mRNA measured by RT-PCR on CD4+ T cells and γδ T cells after 3 days of culture. (f) Representative
histogram, mean frequencies and mean fluorescence intensity quantifying Ki67 expression in Vγ4+ T cells at the end of the 3-day culture. (g) Absolute
number of Vγ4+ γδ T cells after 3 days of culture. Bars are mean+s.d. *Po0.05, **Po0.01 and ***Po0.001 (two-tailed unpaired t-test).
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Th17 cells, respectively) and attenuated their ability to produce IFN-γ
and IL-17A, respectively (Figure 5b). Finally, we found that removal of
γδ T cells prior to in vitro re-stimulation of MOG-primed T cells
significantly impaired the ability of these T cells to induce EAE when
transferred to naive mice (Figure 5c). These results indicate that γδ
T cells contribute to the polarization of both Th1 and Th17 cells,
reflected in their reduced pathogenic activity in the EAE model.
We next examined whether the attenuating effects of RA on
induction of EAE by cell transfer could be mediated directly through
its effect on γδ T cells. Thus, we isolated spleen and draining lymph
node cells from MOG-immunized mice and separated them into γδ
T cells and γδ T-cell-depleted fractions. The γδ T cells were stimulated
for 6 h with IL-1β and IL-23, in the presence of RA or its vehicle,
before being washed thoroughly and cultured with the γδ T-cell-
depleted fraction. The combined cells were then cultured with IL-1β,
IL-23 and MOG for 3 days and transferred to recipient mice. Prior to
transfer, we examined the cytokine profile in the supernatants at the
end of the 3-day culture. Consistent with the treatment of all the cells
with RA, treatment of only the γδ T cells with RA resulted in a
significant reduction of IL-17A and IL-17F production (Figure 6a).
FACS analysis of the cells at the end of the 3-day culture revealed that
IL-17A expression was significantly impaired in γδ T cells and
principally in the Vγ4+ γδ T cells, which constituted the main
IL-17A producers among γδ T cells in our model (Figures 6c
and d). Interestingly, the production of IFN-γ was not affected by the
RA-treated γδ T cells (Figure 6c and data not shown).
We next examined the effect of RA-treated γδ T cells on the
capacity of MOG-specific T cell to induce EAE by adoptive transfer.
Transfer of cells cultured with the vehicle-treated γδ T cells to naive
mice induced EAE by day 6 in these mice (Figure 6d). In contrast, the
onset of the disease was delayed and the severity of the symptoms was
significantly reduced in recipients of the MOG-specific cells containing
the RA-treated γδ T cells (Figure 6d). The frequency and absolute
number of CD4+ T cells producing IL-17A, IFN-γ and GM-CSF was
reduced in the brains of the mice injected with the cells containing
RA-treated γδ T cells (Figures 6e and f and data not shown). Taken
together, our findings provide further evidence of a pathogenic role for
γδ T cells in central nervous system autoimmunity, and demonstrate
that treatment of these cells with RA impairs their IL-17A production,
especially by the Vγ4+ subtype, which results in significant attenuation
of their pathogenic function in vivo.
RA inhibits the IL-1β and IL-23 pathway in γδ T cells
We investigated the mechanisms by which RA modulates activation of
γδ T cells. We first assessed the effect of RA on γδ T cells purified
from naive mice. We found that, within 3 h of culture with IL-1β and
IL-23, RA inhibited the expression of the receptors subunits for IL-1β
and IL-23, which transduce the signals to promote IL-17A and IL-17F
expression in γδ T cells (Figure 7a). Interestingly, stimulation of
purified γδ T cells with IL-12 and IL-18, which are more potent
stimuli for IFN-γ production, induced low concentration of IL-17A,
which was significantly enhanced by RA, while the production of
IL-17A induced by IL-1β and IL-23 was inhibited by RA (Figures 7b
and c). In contrast, RA did not affect IFN-γ production by purified γδ
T cells stimulated with IL-12 and IL-18 or IL-1β and IL-23
(Figure 7b). Moreover, RA did not impair IL-17 production by
CD4+ T cells and γδ T cells in cultures of spleen and LN cells
stimulated with MOG alone (Figure 7d). We then examined the effect
of RA on expression of il1r1 and il23r on purified γδ T cells from
MOG-immunized mice. The results revealed that RA inhibited the
expression of il1r1 and il23r in γδ T cells and principally in the Vγ4+
γδ T-cell subset (Figures 7e and f) and dramatically reduced the
number of Vγ4+ γδ T cells expressing cell surface receptors for IL-1β
and IL-23 (Figure 7g). The activation of the IL-1β/IL-23 pathway is
known to involve the phosphorylation of STAT3, which induces
Th17-type cytokine in IL-17-producing cells.20 We found that treat-
ment of cells from MOG-immunized mice with RA inhibited STAT3
phosphorylation (Figure 7h). Taken together, our data demonstrate
that RA affects the expression of the receptors for IL-1β and IL-23 at
the surface of γδ T cells, resulting in an impaired response of these
cells to IL-1β and IL-23.
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Figure 5 Depletion of γδ T cells attenuates EAE induced by T-cell transfer.
Spleen and lymph node cells from MOG-immunized mice were depleted of
γδ T cells or un-depleted. Cells were cultured for 3 days with MOG, IL-1β
+IL-23, and then 15×106 cells were transferred to naive mice. (a) IL-17A,
IL-17F and IFN-γ concentration measured by ELISA in supernatants the
cultures after 3 days. (b) Representative FACS plots of IL-17A, RORγt, IFN-γ
and Tbet expression in T helper cells at the end of the 3-day culture.
(c) EAE clinical scores of recipient mice. Data are representative of two
independent experiments and are shown as mean+s.d. (a) or mean± s.e.m.
(c). Statistics were calculated using two-tailed unpaired t-test (a) or a
two-way analysis of variance with Bonferroni post-test (c). *Po0.05,
**Po0.01 and ***Po0.001.
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DISCUSSION
In this study, we demonstrate that RA significantly inhibits the
function of IL-17A-producing γδ T cells, impairing their proliferation,
cytokine production and their pathogenic activity in vivo in the EAE
model. In addition, we show that under steady state conditions and
during inflammation, RA also inhibits cytokine production by Th17
cells, which are considered to be the primary pathogenic T cells in
EAE and other autoimmune diseases. Our findings suggest that a
significant component of the attenuating effect of RA in immune-
mediated disease is mediated through its effect on γδ T cells and in
particular on the Vγ4+ subtype. Finally, we show that RA has a
selective suppressive effect on IL-17A and IL-17F production by γδ
T cells, with little effect on IFN-γ, which is explained by its inhibitory
effect on the IL-1β/IL-23 signaling pathway.
Following the discovery of Th17 cells, these cells have become the
main focus of attention as mediators of pathology in many auto-
immune diseases, including EAE–a mouse model for MS.21,22 Indeed,
IL-17A− /− mice are resistant to the development of EAE and the
administration of anti-IL-17A-neutralizing antibody during the early
stages of EAE delays the onset of the symptoms.23,24 However, γδ
T cells have also been shown to be an important source of IL-17A and
to have a key pathogenic role in EAE.3 Previous studies on the effect of
RA on IL-17-producing T cells have focused on CD4+ T cells; it has
been reported that AM80, a RARα agonist, inhibits IL-17 production
by Th17 cells.15 However, this and other studies on the effect of RA or
vitamin A deficiency did not examine the effect on γδ T cells.
We report that RA has a potent inhibitory effect on IL-17 production
by γδ T cells and in particular on the Vγ4+ subtype that is pathogenic
in EAE. Vγ4Vδ4+ cells are the main IL-17-producing-γδ T-cell
subtype in a model of collagen-induced arthritis.25 Although we did
not examine Vγ4+Vδ4+, we did examine the effect of RA on purified
Vγ4+ and Vγ1+ cells and while Vγ4+ were the predominant IL-17
producing cells, IL-17 production by both subtypes was inhibited by
RA. Importantly, we demonstrated that RA had a greater effect
on IL-17-producing γδ T cells than Th17 cells. One explanation
for this observation may be that when compared with Th17 cells,
IL-17-producing γδ T cells respond very quickly and strongly to the
inflammatory cytokines IL-1β and IL-23 (inhibited by RA), without a
need of TCR stimulation. It is also possible that IL-17-producing γδ
T cells may express higher levels of nuclear receptors for RA.
We and others have previously reported that γδ T cells are an
important source of IL-17 and related cytokines in the development of
EAE and have demonstrated that γδ T cells as well as producing early
IL-17 also promote activation of Th17 cells.3,5,8 Consistent with these
findings, the present study demonstrates that the differentiation of
Th17 and Th1 cells and the production of their associated cytokines
IL-17A, IL-17F and IFN-γ are impaired when γδ T cells are depleted
from spleen and lymph node cells from MOG-immunized mice and
stimulated in vitro with MOG, IL-1β and IL-23. Thus, the reduction in
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Figure 6 Selective treatment of γδ T cells with RA decreases the production
of IL-17A and IL-17F during EAE and alters the capacity of T cells from
MOG-immunized mice to induce EAE by cell transfer. Spleen and lymph
node cells from MOG-immunized mice were isolated and the γδ T cells
purified and cultured separately with RA or its vehicle for 6 h before being
put back in culture with the rest of the cells. The total cells containing
either the vehicle- or the RA-treated γδ T cells were then cultured with
MOG, IL-1β and IL-23. After 3 days of culture, 10×106 cells were
transferred to naive mice. (a) IL-17A and IL-17F expression as measured by
ELISA in the supernatants at the end of the 3-day culture. (b) Mean
absolute numbers of IL-17A+, IL-17F+ and IFN-γ+ Vγ4+ γδ T cells at the end
of the 3-day culture. (c) Representative FACS plots indicating the proportion
of IL-17A+ Vγ4+ and IL-17A+ Vγ4− γδ T cells at the end of the 3-day
culture. (d) EAE clinical scores of recipient mice. (e) Representative FACS
plots indicating the proportion of IL-17A+ CD4+ T cells in the brains of the
recipient mice on day 25 post transfer. (f) Absolute numbers of infiltrating
IL-17A+, IFN-γ+ and GM-CSF+ CD4+ T cells in the brains of the recipient
mice on day 25 post transfer. Data are representative of two independent
experiments. Bars are mean+s.d. (a, b), mean± s.e.m. (d) or mean+s.e.m.
(f). Statistics are performed as and two-tailed unpaired t-test (a–c and f) or
two-way analysis of variance with Bonferroni post-test (d); *Po0.05,
**Po0.01 and ***Po0.001.
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pathogenic cytokines observed with RA treatment can be attributed to
a combination of a direct effect of RA on IL-17 production by γδ
T cells and an indirect effect of impaired IL-17 production by γδ
T cells on Th1- and Th17-cell differentiation. Furthermore, the
reduced IFN-γ production observed after depletion of γδ T cells
reflect a removal of IFN-γ-secreting γδ T cells and impaired
differentiation of Th1 cells. This is consistent with our demonstration
that depletion of γδ T cells from the cultures impaired the ability of
T cells to induce EAE when transferred to naive recipient mice. We
have previously shown that RA protects against the development of
colitis by inducing IL-22 production by both γδ T cells and ILC3.18
Here, we show that in the adoptive transfer model of EAE, while RA
reduces cytokine production by Th17 cells, it has a more dramatic
effect on γδ T cells, impairing their proliferation, RORγt expression
and production of IL-17A and IL-17F. Recipient mice injected with
RA-treated T cells developed very mild EAE with delayed onset when
compared with that seen after transfer of untreated cells. Furthermore,
central nervous system infiltration of CD4+ and γδ T cells producing
IL-17A, IL-17F, GM-CSF and IFN-γ was strongly impaired in mice
injected with RA-treated cells. Moreover, we demonstrate that the
treatment of γδ T cells only with RA conferred significant protection
against the development of EAE in the recipient mice, and this was
associated with a significant decrease in the number of IL-17A,
GM-CSF and IFN-γ producing CD4+ T cells infiltrating the brain.
IL-1β and IL-23 are key pathogenic cytokines, which drive the
development of many autoimmune diseases.19,21 Mice deficient for the
IL-1β receptor IL-1R1 or mice lacking the IL-23 subunit IL-23p19 are
resistant to induction of EAE.3,26,27 Interestingly, we demonstrate that
RA directly inhibits the expression of the receptors for IL-1β and
IL-23, IL-1R1 and IL-23R respectively, on activated γδ T cells in vitro.
Finally, we demonstrate that RA impairs the IL-23 pathway by
inhibiting phosphorylation of the transcriptional activator of il17a
and il17f, STAT3.28
There is convincing evidence from animal models that Th17 cells
and more recently IL-17-secreting γδ T cells have crucial pathogenic
roles in EAE and other autoimmune diseases. However, the role of
IFN-γ, produced by Th1 cells, CD8+ T cells and NK cells is less
clear.29–31 Interestingly, we find little effect of RA on IFN-γ production
by CD4+ T cells or even when γδ T cells are cultured with IL-12 and
IL-18, the classical stimuli for IFN-γ production.
It has been reported that RA synergizes with TGF-β to induce
Treg cells, especially in the gut in a steady state.10 Moreover, in the pro-
inflammatory context of collagen-induced arthritis, a mouse model of
rheumatoid arthritis, RA has a protective effect against the development
of the disease by promoting Foxp3+ Treg cells, as well as inhibiting the
differentiation of autoreactive Th17 cells.32 In the EAE model, TGF-β
protects against disease by inducing Foxp3+ Treg cells, which migrate
into the central nervous system and counterbalance the ratio of effector
to Treg cells.33 Moreover, this effect is mediated through IL-10.33 We
found that while RA induces the expression of TGF-β during EAE, the
production of IL-10 is decreased (unpublished observations), indicating
that RA does not protect against disease by inducing Treg cells.
Interestingly, Klemann and colleagues15 demonstrated that a RARα
agonist inhibited EAE induced by active immunization. Collectively,
these findings suggest that in the context of inflammatory responses,
RA can exert immunosuppressive effects on effector T cells.11
In this study, we provide further evidence that γδ T cells have a
significant pathogenic role in EAE, directly or through the activation
of Th17 cells. Furthermore, we show that RA can suppress IL-17A and
IL-17F production by γδ T cells, thereby attenuating their pathogenic
activity in vivo in central nervous system autoimmunity. Our results
provide new insight into the mechanisms of action of RA and
demonstrate that RA selectively inhibits the production of pathogenic
cytokines in autoimmune disease. The findings also provide further
evidence for the potential of targeting γδ T cells in the treatment of
autoimmune diseases.
METHODS
Mice
C57BL/6 mice (Harlan, Bicester, UK) were bred under specific pathogen free
conditions and maintained according to European Union regulations. All
experiments were performed under license from the Health Products Reg-
ulatory Authority and with approval from the Trinity College Dublin Animal
Research Ethics Committee. The mice were co-housed for every EAE
experiment.
Stimulation and FACS analysis of peritoneal exudate cells
Mice were injected intraperitoneally with 250 μg of RA or vehicle (dimethyl
sulfoxide) in phosphate-buffered saline. After 18 h, the mice were killed
and the peritoneal exudate cells collected and cultured for 2 h with phorbol
12-myristate 13-acetate (Sigma-Aldrich, St Louis, MO, USA, 10 ngml− 1),
ionomycin (Sigma-Aldrich, 1 μgml− 1) in the presence of brefeldin A
(5 μgml− 1). Cytokine production was assessed by intracellular cytokine
staining and FACS analysis of the cells.
Induction and assessment of EAE by adoptive transfer
Donor mice were immunized subcutaneously with 100 μg of MOG35-55 peptide
(GenScript, Piscataway, NJ, USA) emulsified in complete Freund’s adjuvant
containing 4 mgml− 1 (0.4 mg per mouse) heat-killed Mycobacterium tubercu-
losis (Chondrex, Redmond, WA, USA). After 10 days, the mice were killed,
their brachial, axillary and inguinal lymph nodes and spleens were collected and
a single cell suspension was prepared. The cells were then stimulated for 3 days
at a concentration of 10× 106 cells per ml with medium, MOG (100 μg ml− 1)
or with MOG, IL-1β (Immunotools, Friesoythe, Germany, 10 ngml− 1) and
IL-23 (R&D Systems, 10 ngml− 1) and with RA (Enzo, Farmingdale, NY, USA,
10− 6 M) or its vehicle (ethanol). In some experiments, γδ T cells were purified
by magnetic-activated cell sorting (Miltenyi, Bergisch Gladbach, Germany,
purity490%; Supplementary Figure 1) prior to the culture and either depleted
from the culture or added back to the rest of the cells (control). The cells were
then stimulated for 3 days with MOG, IL-1β and IL-23. In other experiments,
γδ T cells were magnetic-activated cell sorting-purified prior to the culture and
stimulated separately with IL-1β, IL-23 and RA or its vehicle for 6 h. γδ T cells
were washed thoroughly, put back with the rest of the cells and the total cells
were then stimulated with MOG, IL-1β and IL-23 for 3 days. Cytokine
production was assessed by intracellular cytokine staining and FACS analysis of
the cells or by ELISA (R&D Systems, Minneapolis, MN, USA and BD
Biosciences, San Jose, CA, USA) on the supernatants. For transfer to recipient
animals, the cells were thoroughly washed and 10–15× 106 live cells were
injected intraperitoneally into co-housed recipient mice. The animals were
weighed and monitored for signs of EAE daily. The disease severity was assessed
as follows: 0, no clinical sign; 1, limp tail; 2, ataxic gait; 3, hind limb weakness;
4, hind limb paralysis; 5, tetraplegia/moribund.
Isolation and FACS analysis of brain cells
Mice were killed and perfused with phosphate-buffered saline, and their brains
were isolated. Brain mononuclear cells were then purified by density gradient
centrifugation in Percoll and stimulated for 5 h with phorbol 12-myristate 13-
acetate (Sigma-Aldrich, 10 ngml− 1), ionomycin (Sigma-Aldrich, 1 μgml− 1) in
the presence of brefeldin A (5 μgml− 1) and then stained for intracellular
cytokines and analyzed by FACS.
Purification and culture of γδ T cells
γδ T cells were purified from lymph node cells by magnetic-activated cell
sorting (purity490%; Supplementary Figure 1) and CD27+ and CD27− or
Vγ1+ and Vγ4+ γδ T cells were sorted by FACS (Dako Moflo, Beckman
Coulter, Indianapolis, IN, USA). The cells were stimulated with IL-1β and IL-23
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il1r1 and il23r mRNA measured by RT-PCR in γδ T cells purified from naive mice and cultured for 3 h with IL-1β+IL-23, with or without RA. (b, c) γδ
T cells purified from lymph nodes of naive mice were cultured for 24 h with IL-1β+IL-23 or IL-12+IL-18, and with or without RA. Mean frequencies (b) and
corresponding FACS plots (c) of IL-17A+ Vγ4+ CCR6+ γδ T cells and IFN-γ+ γδ T cells in the culture. (d) Cells from MOG-immunized mice were cultured with
vehicle, MOG or MOG+RA for 24 h and absolute numbers of IL-17A+ γδ T cells and CD4 T cells were determined by FACS. (e–g) Cells from MOG-immunized
mice were cultured for 3 days with MOG, IL-1β and IL-23 and either RA or its vehicle. (e) Relative expression of il1r1 and il23r mRNA measured by RT-PCR
on γδ T cells sorted at the end of the 3-day culture. (f, g) Representative FACS plots (f) and mean frequencies (g) of IL-1R1 and IL-23R expression on Vγ4+
T cells after 3 days of culture. (h) Western blots showing the effect of RA on STAT3 phosphorylation (pSTAT3) with actin as a control after 24, 48 and 72 h
of culture (V: vehicle). Bars are mean+s.d.; *Po0.05, **Po0.01 and ***Po0.001, two-tailed unpaired t-test.
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(γδ T cells, Vγ1+ and Vγ4+ γδ T cells), or with IL-12 and IL-18 (γδ T cells),
together with RA (10− 6 M) or its vehicle (ethanol) for 3 h (RT-PCR),
24 h (flow cytometry) or 72 h (ELISA). The concentrations of the
cytokines IL-17A, IL-17F and IFN-γ in culture supernatants were quantified
by ELISA.
Flow cytometry
Brefeldin A (Sigma-Aldrich, 5 μgml− 1) was added to the cell cultures for 4 h.
Cells were washed before being incubated with a live/dead stain and then
surface-stained with antibodies specific for CD3, CD4, CD8, δTCR, Vγ1, Vγ4,
IL-1R1, IL-23R and CCR6. The cells were washed, fixed and permeabilized
using 2% PFA (Pierce, Walthman, MA, USA) or the Foxp3/Transcription
Factor Staining Buffer Set (eBioscience, San Diego, CA, USA), which allow the
staining of intranuclear proteins. The cells were stained in 0.5% saponin
(Sigma-Aldrich) or permeabilization buffer (eBioscience) containing antibodies
directed against IL-17A, IL-17F, IFN-γ, GM-CSF, RORγt, Tbet and Ki67. Cells
were analyzed using a flow cytometer LSRFortessa (BD) and the data were
analyzed with FloJo software. The FACS profile for the different intracellular
and surface proteins analyzed were established by gating on single, then live
cells and further on CD3+ TCRδ+ for γδ T cells; CD3+TCδ+ Vγ1+ for Vγ1+ γδ
T cells; CD3+TCRδ+Vγ4+ for Vγ4+ γδ T cells; CD3+ TCRδ+Vγ4+CCR6+ for the
IL-17A-producing Vγ4+ γδ T cells; CD3+ TCRδ−CD8−CD4+ for CD4+ T cells.
Reverse transcription-PCR
RNA was extracted from the cells using TRIzol (Invitrogen, Grand Island, NY,
USA) and reverse transcribed into cDNA using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). Rara, il17a, il17f,
rorc, il1r1 and il23r expression were quantified by RT-PCR using commercially
available primers and an ABI PRISM7500 Sequence Detection System (Applied
Biosystems). The amount of each cytokine was determined by normalization to
18S rRNA.
Western blots
Cells were resuspended in ice-cold lysis buffer (50 mM Tris, 150 mM NaCl,
10% glycerol, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
10 mM NaF, 1.5 mM Na3VO4 and 1 mM EDTA), supplemented with
SIGMAFAST protease inhibitors (Sigma-Aldrich) and benzonase (Merck
Millipore, Billerica, MA, USA, 25 U per cell pellet), and lysed for 30 min at
4 °C with rotation. Samples were then centrifuged at 17 000 g for 20 min at 4 °
C. Supernatants were assayed for protein concentration using the Pierce
660 nm protein assay and diluted to the same protein concentration with lysis
buffer. Aliquots corresponding to 10 μg of cell protein were diluted with 5×
SDS-PAGE sample buffer, heated to 95 °C for 10 min and centrifuged at 12 000
g for 5 min at room temperature. Samples were run on a 10% SDS-PAGE gel,
transferred to polyvinylidene difluoride and analyzed by immunoblot using
polyclonal rabbit antibody raised against mouse phospho-STAT3 (Cell Signal-
ing, Danvers, MA, USA), mouse monoclonal antibody raised against beta actin
(Abcam, Cambridge, MA, USA), anti-mouse IgG, HRP conjugate (Promega,
Fitchburg, WI, USA) and anti-rabbit IgG, HRP conjugate (Dako, Carpinteria,
CA, USA).
Statistics
Statistical analysis was performed using GraphPad Prism 5. Analysis of variance
with Bonferroni post-test or Student t test were used to compare statistical
differences of means between groups.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This work was supported by a Science Foundation Ireland Principal investigator
grant (#11/PI/1036) to KHGM and Marie Curie Intra-European Fellowship
(#629498) to MR and KHGM. We thank Barry Moran for assistance with flow
cytometry.
1 Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate
lymphoid cells. Eur J Immunol 2012; 42: 2221–2231.
2 Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S et al.
gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via
an interleukin-23-dependent mechanism. Immunity 2010; 33: 351–363.
3 Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and
IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17
responses and autoimmunity. Immunity 2009; 31: 331–341.
4 Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ et al. Fate mapping of IL-17-
producing T cells in inflammatory responses. Nat Immunol 2011; 12: 255–263.
5 Odyniec A, Szczepanik M, Mycko MP, Stasiolek M, Raine CS, Selmaj KW. Gammadelta
T cells enhance the expression of experimental autoimmune encephalomyelitis
by promoting antigen presentation and IL-12 production. J Immunol 2004; 173:
682–694.
6 Selmaj K, Brosnan CF, Raine CS. Colocalization of lymphocytes bearing gamma delta
T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis.
Proc Natl Acad Sci USA 1991; 88: 6452–6456.
7 Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH.
Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by
gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 2011; 186:
5738–5748.
8 Wohler JE, Smith SS, Zinn KR, Bullard DC, Barnum SR. Gammadelta T cells in EAE:
early trafficking events and cytokine requirements. Eur J Immunol 2009; 39:
1516–1526.
9 Spahn TW, Issazadah S, Salvin AJ, Weiner HL. Decreased severity of myelin
oligodendrocyte glycoprotein peptide 33 - 35-induced experimental autoimmune
encephalomyelitis in mice with a disrupted TCR delta chain gene. Eur J Immunol
1999; 29: 4060–4071.
10 Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y et al.
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+
regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med
2007; 204: 1757–1764.
11 Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by
retinoic Acid. J Immunol 2014; 192: 2953–2958.
12 Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M et al. Reciprocal TH17
and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:
256–260.
13 Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM et al.
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-
3/Stat-5 independent signaling pathway. Blood 2008; 111: 1013–1020.
14 Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic acid receptor-
alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell
differentiation. Eur J Immunol 2007; 37: 2396–2399.
15 Klemann C, Raveney BJ, Klemann AK, Ozawa T, von Horsten S, Shudo K et al.
Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune
encephalomyelitis. Am J Pathol 2009; 174: 2234–2245.
16 Moline-Velazquez V, Ortega MC, Vila del Sol V, Melero-Jerez C, de Castro F, Clemente D.
The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by
modulating myeloid-derived suppressor cell fate and viability. Neurobiol Dis 2014; 67:
149–164.
17 Zhan XX, Liu Y, Yang JF, Wang GY, Mu L, Zhang TS et al. All-trans-retinoic acid
ameliorates experimental allergic encephalomyelitis by affecting dendritic cell and
monocyte development. Immunology 2013; 138: 333–345.
18 Mielke LA, Jones SA, Raverdeau M, Higgs R, Stefanska A, Groom JR et al. Retinoic acid
expression associates with enhanced IL-22 production by gammadelta T cells and
innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med 2013;
210: 1117–1124.
19 Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1
in the induction of IL-17-producing T cells that mediate autoimmune encephalomye-
litis. J Exp Med 2006; 203: 1685–1691.
20 Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to
therapeutic testing. Nat Rev Immunol 2014; 14: 585–600.
21 Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al.
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.
J Exp Med 2005; 201: 233–240.
22 Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect
2013; 2: e60.
23 Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S et al. IL-17 plays an
important role in the development of experimental autoimmune encephalomyelitis.
J Immunol 2006; 177: 566–573.
24 Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al. A distinct lineage of CD4
T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;
6: 1133–1141.
25 Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL. Exacerbation
of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells.
J Immunol 2007; 179: 5576–5583.
26 Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather
than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
Nature 2003; 421: 744–748.
27 Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical
in the induction but not in the effector phase of experimental autoimmune
encephalomyelitis. J Immunol 2007; 178: 2589–2598.
Immunomodulatory effects of RA on γδ T cells
M Raverdeau et al
772
Immunology and Cell Biology
28 Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C et al. Selective
regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad
Sci USA 2006; 103: 8137–8142.
29 Dungan LS, McGuinness NC, Boon L, Lynch MA, Mills KH. Innate IFN-gamma
promotes development of experimental autoimmune encephalomyelitis: a role for NK
cells and M1 macrophages. Eur J Immunol 2014; 44: 2903–2917.
30 Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H et al. Myelin
antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in
C57BL/6 mice. J Immunol 2001; 166: 7579–7587.
31 El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in
experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 2010; 5:
189–197.
32 Kwok SK, Park MK, Cho ML, Oh HJ, Park EM, Lee DG et al. Retinoic
acid attenuates rheumatoid inflammation in mice. J Immunol 2012; 189:
1062–1071.
33 Selvaraj RK, Geiger TL. Mitigation of experimental allergic encephalomyelitis by TGF-
beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and
infectious tolerance. J Immunol 2008; 180: 2830–2838.
The Supplementary Information that accompanies this paper is available on the Immunology and Cell Biology website (http://www.nature.com/icb)
Immunomodulatory effects of RA on γδ T cells
M Raverdeau et al
773
Immunology and Cell Biology
